Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.80 |
| ▸ | CNR1 | P21554 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22834241 | 0.89 | CNR1 (1.00) | THRBCNR1ALDH1A1POLBGAA | |
| SCHEMBL29615207 | 0.89 | CNR1 (1.00) | THRBCNR1ALDH1A1POLBGAA | |
| SCHEMBL12316818 | 0.87 | POLB (0.69) | THRBCNR1ALDH1A1POLBGAA | |
| SCHEMBL17919329 | 0.84 | CNR1 (0.79) | CNR1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL16562213 | 0.83 | CNR1 (0.73) | CNR1GAASMN1; SMN2KDM4E | |
| SCHEMBL16562261 | 0.82 | CNR1 (0.80) | THRBCNR1ALDH1A1POLBLMNA | |
| SCHEMBL13638083 | 0.82 | GAA (0.74) | THRBCNR1ALDH1A1GAALMNA | |
| SCHEMBL14404818 | 0.82 | GAA (0.74) | THRBCNR1ALDH1A1GAALMNA | |
| SCHEMBL6378503 | 0.81 | CA1 (0.74) | CNR1ALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL28748530 | 0.81 | GAA (0.72) | THRBCNR1ALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | THRB 3794/4885CNR1 1450/4885ALDH1A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.